Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from JCR Pharmaceuticals Co., Ltd. ( (JP:4552) ).
JCR Pharmaceuticals reported a significant improvement in its financial performance for the six months ending September 30, 2025, with net sales increasing by 28.2% year-on-year. The company achieved a net profit attributable to owners of the parent of 1,710 million yen, a notable turnaround from the previous year’s loss. This positive financial outcome reflects the company’s strengthened market position and operational efficiency, potentially enhancing stakeholder confidence and supporting future growth initiatives.
The most recent analyst rating on (JP:4552) stock is a Hold with a Yen601.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.
More about JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd. operates in the pharmaceutical industry, focusing on the development and commercialization of biopharmaceuticals. The company is listed on the Tokyo Stock Exchange and is known for its innovative treatments and therapies, particularly in the field of rare diseases.
Average Trading Volume: 919,859
Technical Sentiment Signal: Strong Sell
Current Market Cap: Yen71.4B
For a thorough assessment of 4552 stock, go to TipRanks’ Stock Analysis page.